Flow cytometry (FCM) and its technological possibilities have greatly advanced in the past decade as an analysis tool for single-cell properties and population distributions of different cell types in bioreactors. Along the way, a few automated real‐time flow cytometry (ART‐FCM) solutions were developed for monitoring bioreactor processes without operator interference over extended periods with a variable sampling frequency. ART‐FCM enables long‐term measurements without missing any important events in bioprocesses and uncovers temporal phenomena that are likely unknown and should be investigated in greater detail. Also, more frequent measurements can be performed at a user-defined frequency, independent of the availability of personnel. When compared with methods such as omics that are only partially available on a single-cell level, multi-parameter measurements can be easily established without the extended effort of labor and time via ART-FCM. Compared with conventional FCM studies, microfluidic devices great future potential as ART‐FCM on a chip. In this context, parallelization might become more relevant, as samples from different bioreactors or different locations inside a bioreactor setup could be analyzed simultaneously. Many aspects might also be adapted to other experimental setups where fast and reproducible real‐time monitoring of fluorescent process parameters is also of interest. In conclusion, ART‐FCM will most probably advance exponentially in the upcoming years.
The bioprocessing capacity globally has increased at an average of 12% since the past decade, as per the BioPlan Associates Top 1000 Biofacility Index and Biomanufacturers Database report. China is well positioned as a global participant in markets with both small and large-molecule drugs, accounting for second and third position, respectively, worldwide. Also, China is home to several developers of cell and gene therapy due to China's base for contract development and manufacturing organizations (CDMOs), accounting for ~25% of the country's bioproduction capacity. Therefore, China has considerable biomanufacturing capabilities but strict adherence to the global GMP standards that build confidence in the biologics' safety and effectiveness.
Asia Pacific Bioprocess Technology Market Segmentation
The Asia Pacific bioprocess technology market is segmented into type, modality, end user, and country.
Based on type, the Asia Pacific bioprocess technology market is segmented into cell culture media bioprocess, chromatography bioprocess, consumables & accessories, and others. In 2023, the consumables & accessories segment registered the largest share in the Asia Pacific bioprocess technology market.
Based on modality, the Asia Pacific Bioprocess technology market is bifurcated into single use and multiple use. In 2023, the single use segment registered a larger share in the Asia Pacific bioprocess technology market.
Based on end-use, the Asia Pacific Bioprocess technology market is segmented into academic & medical institutions, biopharmaceutical companies, research laboratories, and others. In 2023, the biopharmaceutical companies segment registered the largest share in the Asia Pacific bioprocess technology market.
Based on country, the Asia Pacific Bioprocess technology market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2023, China segment registered a largest share in the Asia Pacific bioprocess technology market.
Corning Inc; Danaher Corp; Eppendorf SE; Lonza Group AG; Merck KGaA; Repligen Corp; Sartorius AG; and Thermo Fisher Scientific Inc are the leading companies operating in the Asia Pacific bioprocess technology market.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 4,608.64 Million |
| Market Size by 2028 | US$ 11,000.75 Million |
| CAGR (2023 - 2028) | 19.0% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2028 |
| Segments Covered |
By Type
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
The Asia Pacific Bioprocess Technology Market is valued at US$ 4,608.64 Million in 2023, it is projected to reach US$ 11,000.75 Million by 2028.
As per our report Asia Pacific Bioprocess Technology Market, the market size is valued at US$ 4,608.64 Million in 2023, projecting it to reach US$ 11,000.75 Million by 2028. This translates to a CAGR of approximately 19.0% during the forecast period.
The Asia Pacific Bioprocess Technology Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Bioprocess Technology Market report:
The Asia Pacific Bioprocess Technology Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Bioprocess Technology Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Bioprocess Technology Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Bioprocess Technology Market
